# A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)

> **NCT05673928** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 30 (estimated)

## Conditions studied

- Metastatic Solid Tumor
- Brain Metastases

## Interventions

- **DRUG:** Trastuzumab emtansine
- **DRUG:** Tucatinib

## Key facts

- **NCT ID:** NCT05673928
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-16
- **Primary completion:** 2027-03-01
- **Final completion:** 2029-03-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-01-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05673928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05673928, "A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT05673928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*